Academic article

• Wan Ting Tay; Tiew Hwa Katherine Teng; Wouter Ouwerkerk et al. (2025). Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry. (external link)
• Emil Wolsk; Brian Claggett; Rafael Diaz et al. (2022). Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients With coronary artery disease and type 2 diabetes. (external link)
• Jonathan Howlett; Josep Comin-Colet; Kenneth Dickstein et al. (2018). Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. (external link)
• Paloma Pandhi; Jozine M. ter Maaten; Stefan D. Anker et al. (2022). Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure. (external link)
• Niels Grote Beverborg; Haye H. van der Wal; IJsbrand T. Klip et al. (2019). Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients with Heart Failure: Results from the DEFINE-HF and BIOSTAT-CHF Studies. (external link)
• Henry Krum; John J.V. McMurray; William T. Abraham et al. (2015). The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics. (external link)
• Candace D. McNaughton; Alex McConnachie; John G. Cleland et al. (2022). Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure). (external link)
• Kenneth Dickstein; Gilbert W. Gleim; Steven Snappin et al. (2006). The impact of morbid events on survival following hospitalization for complicated myocardial infarction. (external link)
• Paolo Gatti; Cecilia Linde; Lina Benson et al. (2023). What determines who gets cardiac resynchronization therapy in Europe? A comparison between ESC-HF-LT registry, SwedeHF registry, and ESC-CRT Survey II. (external link)
• Ali A. Al-Mubarak; Niels Grote Beverborg; Stefan D. Anker et al. (2020). A clinical tool to predict low serum selenium in patients with worsening heart failure. (external link)
• Rhonda Bentley-Lewis; David Aguilar; Matthew C. Riddle et al. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. (external link)
• Cord A Manhenke; Thor Ueland; Bodh I. Jugdutt et al. (2014). The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. (external link)
• Daan Ceelen; Adriaan A. Voors; Jasper Tromp et al. (2022). Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. (external link)
• Thor Ueland; Pål Aukrust; Arne Yndestad et al. (2005). Soluble CD40 ligand in acute and chronic heart failure. (external link)
• Thong Huy Cao; Wan Ting Tay; Donald J.L. Jones et al. (2024). Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry. (external link)
• George Markousis-Mavrogenis; Jasper Tromp; Wouter Ouwerkerk et al. (2019). The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. (external link)
• Kenneth Dickstein; John Kjekshus (2002). For the OPTIMAAL trial: losartan or captopril after acute myocardial infarction. (external link)
• Kenneth Dickstein; John Kjekshus (2002). Effects of losatan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. (external link)
• S Ørn; Kenneth Dickstein (2000). Pharmacotherapy following myocardial infarction - a review of current treatment practices. (external link)
• Jozine M. ter Maaten; Adriaan A. Voors; Kevin Damman et al. (2018). Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. (external link)
• Josep Comin-Colet; Mitja Lainscak; Kenneth Dickstein et al. (2013). The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. (external link)
• João Pedro Ferreira; Wouter Ouwerkerk; Bernadet T Santema et al. (2021). Differences in biomarkers and molecular pathways according to age for patients with HFrEF. (external link)
• AI Larsen; K Gjesdal; Christian Hall et al. (2004). Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. (external link)
• Jozine M. ter Maaten; Daan Kremer; Biniyam G. Demissei et al. (2019). Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. (external link)
• K Swedberg; Kenneth Dickstein; C Bergh et al. (2000). Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. (external link)
• P Pitt; P Poole-Wilson; R Segal et al. (2000). Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. (external link)
• Thor Ueland; Rune Jemtland; Kristin Godang et al. (2004). Prognostic value of osteoprotegerin in heart failure following acute myocardial infarction. (external link)
• Pooja Dewan; Rasmus Rørth; Pardeep S. Jhund et al. (2019). Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. (external link)
• Duygu Koçyiğit; Nedim Umutay Sarıgül; Timuçin Altın et al. (2022). Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population. (external link)
• João Pedro Ferreira; Kévin Duarte; Bertram Pitt et al. (2018). Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: Findings from the EPHESUS and OPTIMAAL trials. (external link)
• Iziah E. Sama; Rebecca J. Woolley; Jan F. Nauta et al. (2020). A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. (external link)
• Milton Packer; Richard Holcomb; William T. Abraham et al. (2017). Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. (external link)
• Thomas Erik Gundersen; Kenneth Dickstein; Torstein Hole et al. (1997). Betablokkerbehandling av hjertesviktpasienter. (external link)
• Jan Steffel; Niraj Varma; Michele Robertson et al. (2016). Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. (external link)
• Ioana Sus; Radu Vatasescu; Calin Siliste et al. (2020). Cardiac resynchronization therapy in Romania – results from the european society of cardiology CRT survey II. (external link)
• N Tollefsen; Kenneth Dickstein (2000). Er øyeblikkelig hjelp-innleggelser i medisinks avdeling avhengig av været?. (external link)
• Susan Stienen; João Pedro Ferreira; Nicolas Girerd et al. (2019). Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. (external link)
• Torkel Steen; Elena Sciaraffia; Camilla Jaqueline Hansine Normand et al. (2019). Contemporary practice of CRT implantation in scandinavia compared to Europe. (external link)
• Jasper Tromp; Justin A. Ezekowitz; Wouter Ouwerkerk et al. (2023). Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry. (external link)
• P Pitt; P Poole-Wilson; R Segal et al. (2000). Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. (external link)
• N Tollefsen; Kenneth Dickstein (2000). Are emergency medical admissions dependent on the weather?. (external link)
• K Swedberg; Kenneth Dickstein; C Bergh et al. (2000). Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. (external link)
• Ø Hegland; Kenneth Dickstein; J Larsen (2000). Effect of simvastatin in preventing progression of carotid artery stenosis. (external link)
• James P. Curtain; Ross T. Campbell; Mark C. Petrie et al. (2022). Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. (external link)
• T Omland; Kenneth Dickstein; V Bonarjee et al. (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. (external link)
• Kenneth Dickstein; C Manhenke; T Aarsland et al. (2000). The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. (external link)
• V Bonarjee; Kenneth Dickstein (2000). The use of angiotensin II receptor antagonists in heart failure. (external link)
• A Larsen; T Aarsland; Kenneth Dickstein (2000). Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. (external link)
• S Ørn; Kenneth Dickstein (2000). Pharmacotherapy following myocardial infarction - a review of current treatment practices. (external link)
• Kenneth Dickstein; J Kjekshus (2000). Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. (external link)
• Jasper Tromp; Wouter Ouwerkerk; Tiew-Hwa K. Teng et al. (2022). Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. (external link)
• Pooja Dewan; Rasmus Rørth; Pardeep S. Jhund et al. (2019). Differential impact of heart failure with reduced ejection fraction on men and women. (external link)
• Lukas Baumhove; Jasper Tromp; Sylwia Figarska et al. (2022). Heart failure with normal LVEF in BIOSTAT-CHF. (external link)
• Alf Inge Larsen; Karen Blaauw Helle; Monika Christensen et al. (2008). Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. (external link)
• John J.V. McMurray; Henry Krum; William T. Abraham et al. (2016). Aliskiren, enalapril, or aliskiren and enalapril in heart failure. (external link)
• John R. Teerlink; G. Michael Felker; John J.V. McMurray et al. (2016). Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. (external link)
• Spyridon Katsanos; Wouter Ouwerkerk; Dimitrios Farmakis et al. (2023). Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry. (external link)
• P Poole-Wilson; R Segal; M Konstam et al. (2000). Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. (external link)
• T Omland; Kenneth Dickstein; U Syversen (2000). Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. (external link)
• A Larsen; T Aarsland; Kenneth Dickstein (2000). Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. (external link)
• Kenneth Dickstein (2000). Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. (external link)
• Kenneth Dickstein (2000). Exercise training in heart failure. Time to go beyond surrogate endpoints. (external link)
• Bernadet T. Santema; Wouter Ouwerkerk; Jasper Tromp et al. (2019). Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. (external link)
• Angelo Auricchio; Maurizio Gasparini; Cecilia Linde et al. (2019). Sex-related procedural aspects and complications in CRT survey II: A multicenter European experience in 11,088 patients. (external link)
• Kenneth Dickstein; J Kjekshus (2000). Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. (external link)
• Kenneth Dickstein; C Manhenke; T Aarsland et al. (2000). The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. (external link)
• Stein Ørn; S Orn; Cord Arend Manhenke et al. (2009). C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. (external link)
• João Pedro Ferreira; Marco Metra; Stefan D. Anker et al. (2019). Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. (external link)
• Masatake Kobayashi; Adriaan A. Voors; Nicolas Girerd et al. (2019). Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. (external link)
• Svetoslav Lovev; Milena Staneva; Kenneth Dickstein et al. (2018). European crt survey II - bulgarian data. (external link)
• Gerasimos Filippatos; Dimitrios Farmakis; Josep Colin Colet et al. (2013). Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. (external link)
• Sonya K. Hui; Abhinav Sharma; Kieran Docherty et al. (2021). Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: Insights from the high-risk myocardial infarction database. (external link)
• Bhupendar Tayal; John Gorcsan; Jeroen J. Bax et al. (2018). Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes. (external link)
• Matteo Pagnesi; Marianna Adamo; Iziah E. Sama et al. (2022). Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. (external link)
• Pooja Dewan; João Pedro Ferreira; Jawad H. Butt et al. (2023). Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE. (external link)
• Eva M. Boorsma; Jozine M. ter Maaten; Kevin Damman et al. (2021). Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure. (external link)
• V Bonarjee; Kenneth Dickstein (2000). Bruk av angiotensin II - reseptorblokkere ved hjertesvikt. (external link)
• Kenneth Dickstein (2000). Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. (external link)
• Kenneth Dickstein (2000). Exercise training in heart failure. Time to go beyond surrogate endpoints. (external link)
• Nigussie Bogale; Stein Ørn; Margaret K. James et al. (2007). Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. (external link)
• Kenneth Dickstein (2001). AllAs in congestive heart failure: Insights from ELITE II and ValHeft. (external link)
• Adriaan A. Voors; Stephan von Haehling; Stefan D. Anker et al. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. (external link)
• Jasper Tromp; Joost C. Beusekamp; Wouter Ouwerkerk et al. (2022). Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. (external link)
• Ida Gustafsson; Caroline N. Kistorp; Margaret K. James et al. (2007). Unrecognized glycometabolic disturbance as measured by hemoglobin A(1c) is associated with a poor outcome after acute myocardial infarction. (external link)
• Da-Yi Hu; Jun Huang; Nai-sheng Cai et al. (2012). A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. (external link)
• Alf Inge Larsen; Christian Hall; Pål Aukrust et al. (2003). Prognostic usefulness of an increase in N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. (external link)
• Michel Komajda; Olivier Hanon; Matthias Hochadel et al. (2009). Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. (external link)
• Ulrik M. Mogensen; Pardeep S. Jhund; William T. Abraham et al. (2017). Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. (external link)
• Torbjørn Omland; Kenneth Dickstein; Unni Syversen (2003). Plasma chromogranin A concentration as an indicator of long-term mortality after acute myocardial infarction. (external link)
• Stefan Ørn; Kenneth Dickstein (2003). Neurohumoral inhibition in heart failure; is there no limit?. (external link)
• Christian Hall; Halfdan Ihlen; Vernon Bonarjee et al. (2003). N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. (external link)
• Óscar Cano; Alejandro Bellver; Adolfo Fontenla et al. (2018). Spanish results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). (external link)
• Øyvind Hetland; Anette Knudsen; Kenneth Dickstein et al. (2002). Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. (external link)
• Kim P. Wagenaar; Frans H. Rutten; Leonie Verheijden Klompstra et al. (2017). 'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. (external link)
• Kim P. Wagenaar; Berna D.L. Broekhuizen; Kenneth Dickstein et al. (2015). Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: Design of the multicentre randomized e-Vita heart failure trial. (external link)
• Koen W. Streng; Hans L. Hillege; Jozine M. ter Maaten et al. (2023). Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. (external link)
• Markku S. Nieminen; Veli-Pekka Harjola; Matthias Hochadel et al. (2008). Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. (external link)
• Alice Ravera; Bernadet T. Santema; Iziah E. Sama et al. (2021). Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. (external link)
• Riccardo M. Inciardi; Matteo Pagnesi; Carlo M. Lombardi et al. (2022). Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. (external link)
• Pooja Dewan; Alice Jackson; Pardeep S. Jhund et al. (2020). The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. (external link)
• Niels Grote Beverborg; Ridha I.S. Alnuwaysir; George Markousis-Mavrogenis et al. (2024). The transcriptional profile of iron deficiency in patients with heart failure: Heme-sparing and reduced immune processes. (external link)
• John Gorcsan; Peter Søgaard; Jeroen J. Bax et al. (2016). Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: A subgroup analysis of the EchoCRT trial. (external link)
• João Pedro Ferreira; Nicolas Girerd; John Gregson et al. (2018). Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. (external link)
• Emil Wolsk; Brian Claggett; Marc A. Pfeffer et al. (2017). Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. (external link)
• Kenneth Dickstein; John Kjekshus (1999). Comparison of the effects of Losartan and Captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design. (external link)
• Alf Inge Larsen; Sigurd Lindal; Pål Aukrust et al. (2002). Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. (external link)
• Frank Ruschitzka; William T. Abraham; Jagmeet Singh et al. (2013). Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. (external link)
• Kenneth Dickstein; John Kjekshus (2002). Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. (external link)
• Trond Johan Cooper; John G.F. Cleland; Marco Guazzi et al. (2022). Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. (external link)
• Kenneth Dickstein; Panos E. Vardas; Angelo Auricchio et al. (2010). 2010 Focused Update of ESC Guidelines on device therapy in heart failure. (external link)
• Arne Yndestad; Alexandra Finsen; Thor Ueland et al. (2012). The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure. (external link)
• Kenneth Dickstein; Nigussie Bogale; Silvia Giuliana Priori et al. (2009). The European cardiac resynchronization therapy survey. (external link)
• Zied Frikha; João Pedro Ferreira; Erwan Bozec et al. (2018). Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). (external link)
• Jørgen A. Gravning; Stein Ørn; Ole Jørgen Kaasbøll et al. (2012). Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction. (external link)
• T Omland; K Dickstein; Unni Syversen (2003). Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. (external link)
• Cord A Manhenke; Stein Ørn; Stephan von Haehling et al. (2013). Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. (external link)
• Marvin A. Konstam; James D. Neaton; Philip A. Poole-Wilson et al. (2005). Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). (external link)
• Alice Ravera; Bernadet T. Santema; Rudolf A. de Boer et al. (2022). Distinct pathophysiological pathways in women and men with heart failure. (external link)
• Jasper Tromp; Wouter Ouwerkerk; Biniyam G. Demissei et al. (2018). Novel endotypes in heart failure: effects on guideline-directed medical therapy. (external link)
• Teresa Gerhardt; Louisa M S Gerhardt; Wouter Ouwerkerk et al. (2023). Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. (external link)
• Kenneth Dickstein; Panos E. Vardas; Angelo Auricchio (2010). 2010 Focused Update of ESC Guidelines on device therapy in heart failure. (external link)
• Christopher M. O'Connor; RC Starling; AF Hernandez et al. (2011). Effect of nesiritide in patients with acute decompensated heart failure. (external link)
• Sally C. Inglis; Judith Bebchuk; Sultan A. Al-Suhaim et al. (2013). Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. (external link)
• Søren Lund Kristensen; Ulrik M. Mogensen; Georgia Tarnesby et al. (2018). Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. (external link)
• Thor Ueland; Pål Aukrust; Arne Yndestad et al. (2005). Soluble CD40 ligand in acute and chronic heart failure. (external link)
• Stein Ørn; S Orn; John G.F. Cleland et al. (2005). Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. (external link)
• Adriaan A. Voors; Stefan D. Anker; John G. Cleland et al. (2016). A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. (external link)
• Alf Inge Larsen; Kenneth Dickstein (2005). Exercise training in congestive heart failure. A review of the current status. (external link)
• Iain B. Squire; Stein Ørn; Leong L. Ng et al. (2005). Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. (external link)
• Kenneth Dickstein; J. Kjekshus (2001). Comparison of baseline data, initial course, and management: Losartan vs. Captopril following acute myocardial infarction (The OPTIMAAL Trial). (external link)
• Ø. Hetland; Kenneth Dickstein; D. Nilsen (2001). Fibrin monomer (soluble fibrin) as a marker of coagulation activation in patients with acute chest pain syndromes. (external link)
• Kenneth Dickstein; T. Aarsland; R. Hapnes (2001). Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. (external link)
• Marc A. Pfeffer; Brian Claggett; Rafael Diaz et al. (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. (external link)
• Jeroen J. Bax; Victoria Delgado; Peter Søgaard et al. (2017). Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: A subanalysis of the randomized EchoCRT trial. (external link)
• T Omland; T Aarsland; A Aakvaag et al. (1993). The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. (external link)
• A. Larsen; T. Aarsland; M. Kristiansen et al. (2001). Assessing the effect of exercise training in men with heart failure. Comparison of maximal, submaximal and endurance protocols. (external link)
• Kenneth Dickstein (2001). The role of losartan in the management of patients with heart failure. (external link)
• V. Bonarjee; Kenneth Dickstein (2001). How long should ACE inhibitors be given to patients following myocardial infarction: Implications of HOPE. (external link)
• Marte Asphaug; Øyvind Skadberg; Ingvild Dalen et al. (2016). Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization. (external link)
• Thor Ueland; John Kjekshus; Stig Sophus Frøland et al. (2005). Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. (external link)
• Marianna Adamo; Matteo Pagnesi; Mattia Di Pasquale et al. (2024). Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF. (external link)
• Milton Ellen Packer; Christopher M. O'Connor; John J.V. McMurray et al. (2017). Effect of ularitide on cardiovascular mortality in acute heart failure. (external link)
• Bernadet T. Santema; Vicente Artola Arita; Iziah E. Sama et al. (2022). Pathophysiological pathways in patients with heart failure and atrial fibrillation. (external link)
• Stefan Agewall; Liv Tjessem; Patrick Rossignol et al. (2017). Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. (external link)
• Stefan D. Anker; Adriaan A. Voors; Darlington Okonko et al. (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. (external link)
• Athar Ali Tajik; Kenneth Dickstein (2016). What constitutes optimal neurohumoral antagonism in chronic heart failure?. (external link)
• Adriaan A. Voors; Wouter Ouwerkerk; Faiez Zannad et al. (2017). Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. (external link)
• A. I. Larsen; P. Aukrist; T. Aarsland et al. (2001). Effect of aerobic exercise training on plasma levels of tumor necosis factor alpha in patients with heart failure. (external link)
• Cord Arend Manhenke; Kenneth Dickstein (2001). Digitalis ved hjertesvikt - fortsatt et aktuelt behandlingsprinsipp?. (external link)
• Øivind Hegland; Kenneth Dickstein; Jan P. Larsen (2001). Effect of simvastatin in preventing progression of carotid artery stenosis. (external link)
• Kenneth Dickstein (2001). ELITE II and ValHeft; Together what do they tell us?. (external link)
• Stefano Coiro; Nicolas Girerd; Patrick Rossignol et al. (2017). Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. (external link)
• Kim P. Wagenaar; Berna D.L. Broekhuizen; Tiny Jaarsma et al. (2018). Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial. (external link)
• Trond Johan Cooper; Marco Guazzi; Abdallah Al-Mohammad et al. (2013). Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. (external link)
• Alf Inge Larsen; Clara Gram Gjesdal; C. Hall et al. (2004). Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. (external link)
• Janice Y. Chyou; Wan Ting Tay; Jasper Tromp et al. (2025). Prognostic Implications and Global Perspectives of Atrial Fibrillation in Patients Hospitalized for Heart Failure. (external link)
• Alf Inge Larsen; Øyvind Skadberg; Torbjørn Aarsland et al. (2009). B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. (external link)
• S.M. Afzel Sohaib; Zhongbo Chen; Zachary I. Whinnett et al. (2013). Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. (external link)
• Franco Cosmi; Li Shen; Michela Magnoli et al. (2018). Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. (external link)
• Thor Ueland; Rune Jemtland; Kristin Godang et al. (2004). Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. (external link)
• Nigussie Bogale; Silvia Giuliana Priori; Anselm Gitt et al. (2011). The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. (external link)
• Kenneth Dickstein; Camilla Jaqueline Hansine Normand; Angelo Auricchio et al. (2018). CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?. (external link)
• Wouter Ouwerkerk; Jasper Tromp; John G.F. Cleland et al. (2022). Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. (external link)
• Kenneth Dickstein; AI Larsen; Vernon Bonarjee et al. (1996). Pro-atrial natriuretisk faktor i plasma er prediktiv for klinisk status hos hjertesviktpasienter. (external link)
• João Pedro Ferreira; Nicolas Girerd; Pierpaolo Pellicori et al. (2016). Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. (external link)
• Johannes FE Mann; Roland E Schmieder; Matthew McQueen et al. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. (external link)
• Vasiliki Bistola; Dimitrios Farmakis; Jasper Tromp et al. (2024). Hospitalized Advanced Heart Failure With Preserved vs Reduced Left Ventricular Ejection Fraction: A Global Perspective. (external link)
• Wilfried Mullens; Angelo Auricchio; Pieter Martens et al. (2021). Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. (external link)
• Trond Johan Cooper; Stefan D. Anker; Josep Comin-Colet et al. (2016). Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia. (external link)
• Koen W. Streng; Jan F. Nauta; Hans L. Hillege et al. (2018). Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. (external link)
• Jan F. Nauta; Yoran M. Hummel; Jasper Tromp et al. (2019). Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. (external link)
• João Pedro Ferreira; Nicolas Girerd; Kevin Duarte et al. (2017). Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction: an analysis from the High-Risk Myocardial Infarction Database Initiative. (external link)
• Gerasimos Filippatos; Christiane E. Angermann; John G.F. Cleland et al. (2020). Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. (external link)
• Stefan D. Anker; Joseph C Colet; Gerasimos Filippatos et al. (2009). Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. (external link)
• Matthias P. Nägele; Jan Steffel; Michele Robertson et al. (2017). Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. (external link)
• Anaïs Gauthey; Rik Willems; Yves Vandekerckhove et al. (2019). Benchmarking Belgian CRT practice against the rest of Europe: insights from the ESC-CRT survey II. (external link)
• Mateusz Tajstra; Damian Łasocha; Elżbieta Gadula-Gacek et al. (2019). Cardiac resynchronization in Poland – comparable procedural routines? Insights from CRT Survey II. (external link)
• Eric S. Ketchum; Kenneth Dickstein; John Kjekshus et al. (2014). The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. (external link)
• Deepti Ranganathan; Zain Sharif; Theodore Murphy et al. (2020). CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis. (external link)
• Dirk J. van Veldhuisen; Alexander H Maass; Silvia Giuliana Priori et al. (2009). Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. (external link)
• Paloma Pandhi; Koen W. Streng; Stefan D. Anker et al. (2021). The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. (external link)
• Torgeir W. Sørbye; Christian L. Ellingsen; Kenneth Dickstein (2002). Prioritering av sykehusobduksjon. (external link)
• Marvin A Konstam; Philip Alexander Poole-Wilson; Kenneth Dickstein et al. (2008). Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. (external link)
• Carlo Lombardi; João Pedro Ferreira; Valentina Carubelli et al. (2020). Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. (external link)
• Athar Ali Tajik; Daniela Dobre; David Aguilar et al. (2017). A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. (external link)
• Stein Ørn; Kenneth Dickstein (2002). How do heart failure patients die?. (external link)
• Massimo F Piepoli; Viviane Conraads; Ugo Corra et al. (2011). Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. (external link)
• João Pedro Ferreira; Wouter Ouwerkerk; Jasper Tromp et al. (2019). Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. (external link)
• Alf Inge Larsen; Kenneth Dickstein; Seyed Nasser Ahmadi et al. (2006). The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. (external link)
• Dennis Lawin; Carsten W. Israel; Cecilia Linde et al. (2019). Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. (external link)
• Kenneth Dickstein; Panos E. Vardas; Angelo Auricchio et al. (2010). Update of ESC guidelines regarding usage of devices in patients with heart failure-2010. (external link)
• Thor Ueland; Terje Espevik; John Kjekshus et al. (2006). Mannose binding lectin and soluble Toll-lilke receptor 2 in heart failure following acute myocardial infarction. (external link)
• João Pedro Ferreira; Marco Metra; Ify Mordi et al. (2018). Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. (external link)
• Li Shen; Felix Ramires; Felipe Martinez et al. (2017). Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. (external link)
• Vincent M. van Deursen; Adrian F. Hernandez; Amanda Stebbins et al. (2014). Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF).. (external link)
• Beth A. Davison; Stefanie Senger; Iziah E. Sama et al. (2020). Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. (external link)
• Rebecca J. Woolley; Daan Ceelen; Wouter Ouwerkerk et al. (2021). Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. (external link)
• Lukas Baumhove; Nils Bomer; Jasper Tromp et al. (2023). Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D. (external link)
• João Pedro Ferreira; Patrick Rossignol; Jean-Loup Machu et al. (2017). Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. (external link)
• Sung-Hee Shin; Brian Claggett; Marc A. Pfeffer et al. (2020). Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. (external link)
• Patrick Rossignol; Kevin Duarte; Nicolas Girerd et al. (2020). Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. (external link)
• Stefano Coiro; Nicolas Girerd; Abhinav Sharma et al. (2019). Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. (external link)
• Mitja Lainscak; Lynda Blue; Andrew L. Clark et al. (2011). Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. (external link)
• Joost C. Beusekamp; Jasper Tromp; Haye H. van der Wal et al. (2018). Potassium and the use of renin?angiotensin?aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. (external link)
• Matteo Pagnesi; Marianna Adamo; Iziah E. Sama et al. (2021). Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. (external link)
• John J. McMurray; Stefan D Anker; Angelo Auricchio et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. (external link)
• Hertzel C. Gerstein; Sibylle Hess; Brian Claggett et al. (2022). Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. (external link)
• Kieran F. Docherty; João Pedro Ferreira; Abhinav Sharma et al. (2020). Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. (external link)
• Thomas Erik Gundersen; Kenneth Dickstein; Torstein Hole et al. (1997). Treatment of heart failure with beta-adrenergic blocking drugs. (external link)
• Márton Tokodi; Annamária Kosztin; Attila Kovács et al. (2024). Machine learning-based prediction of 1-year all-cause mortality in patients undergoing CRT implantation: validation of the SEMMELWEIS-CRT score in the European CRT Survey I dataset. (external link)
• Thong Huy Cao; Donald J.L. Jones; Paulene A. Quinn et al. (2018). Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. (external link)
• Trygve Brügger-Andersen; Volker Pönitz; Steven M. Snapinn et al. (2009). Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction. (external link)
• Øyvind Skadberg; Øyunn Kleiven; Magnus Bjørkavoll-Bergseth et al. (2017). Highly increased Troponin i levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise Study (NEEDED) 2013. (external link)
• Jan Steffel; Michele Robertson; Jagmeet P. Singh et al. (2015). The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: A subgroup analysis of the EchoCRT trial. (external link)
• G. Michael Felker; Peter S. Pang; Kirkwood F. Adams et al. (2010). Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward. (external link)
• Duygu Koçyiğit; Nedim Umutay Sarigul; Timuçin Altın et al. (2020). Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II. (external link)
• A Yndestad; Linn Landrø; Thor Ueland et al. (2009). Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. (external link)
• Luca Monzo; Emmanuel Bresso; kenneth dickstein et al. (2024). Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction. (external link)
• Mette Elise Estensen; Aina Hognestad; Unni Syversen et al. (2006). Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. (external link)
• João Pedro Ferreira; Patrick Rossignol; Biniyam Demissei et al. (2018). Coronary angiography in worsening heart failure: Determinants, findings and prognostic implications. (external link)
• C. Shi; Haye H. van der Wal; Martin Dokter et al. (2020). Tumour biomarkers: association with heart failure outcomes. (external link)
• Tor Harald Melberg; Marianne Jørgensen; Stein Ørn et al. (2014). Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial. (external link)
• Erlend Gyllensten Singsaas; Cord A Manhenke; Kenneth Dickstein et al. (2016). Circulating galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. (external link)
• NS Anavekar; JJV McMurray; EJ Velazquez et al. (2004). Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. (external link)
• Madarar Ventina; Oskars Kalçjs; Maija Vikmane et al. (2020). SECOND EUROPEAN CARDIAC RESYNCHRONISATIONTHERAPY SURVEY (CRT SURVEY II): LATVIAN DATACOMPARED TO EUROPE. (external link)
• Veli-Pekka Harjola; Ferenz Follath; Markku S. Nieminen et al. (2010). Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. (external link)
• Iziah E. Sama; Alice Ravera; Bernadet T. Santema et al. (2020). Circulating plasma concentrations of angiotensin-converting enzyme 2 inmen and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. (external link)
• Marie-Sophie L. Y. de Koning; Johanna E. Emmens; Esteban Romero-Hernández et al. (2023). Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure. (external link)
• Kenneth Dickstein; Silvia Giuliana Priori; Angelo Auricchio et al. (2009). European cardiac resynchronization therapy survey: rationale and design. (external link)
• Kenneth Dickstein; John Kjekshus (2004). Effects of losartan and captopril on morbidity and mortality after acute MI. (external link)
• Bernadet T. Santema; Mariëlle Kloosterman; Isabelle C. Van Gelder et al. (2018). Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. (external link)
• Sandro Brusich; Ivan Zeljković; Nikola Pavlovic et al. (2018). Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry. (external link)
• Eva M. Boorsma; Jozine M. ter Maaten; Kevin Damman et al. (2023). Albuminuria as a marker of systemic congestion in patients with heart failure. (external link)
• Azmil H Abdul-Rahim; Kieran F Docherty; Hicham Skali et al. (2016). Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. (external link)
• Marvin A Konstam; James D. Neaton; Kenneth Dickstein et al. (2009). Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. (external link)
• Stefan D. Anker; Joseph C Colet; Gerasimos Filippatos et al. (2009). Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. (external link)
• Giovanni Luca Botto; Maurizio Gasparini; Francesco M.A. Brasca et al. (2020). Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. (external link)
• Priyesh A. Patel; Gretchen M Heizer; Christopher M. O’Connor et al. (2014). Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality findings from ASCEND-HF. (external link)
• Antoni Bayes-Genis; Julio Núñez; Faiez Zannad et al. (2017). The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. (external link)
• Kenneth Dickstein; Panos E. Vardas; Angelo Auricchio et al. (2010). 2010 Focused Update of ESC Guidelines on device therapy in heart failure An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. (external link)
• Kenneth Dickstein; Panos E. Vardas; Angelo Auricchio et al. (2010). 2010 Focused Update of ESC Guidelines on device therapy in heart failure. (external link)
• Lars Gullestad; Stein Ørn; Kenneth Dickstein et al. (2013). Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. (external link)
• Marco Guazzi; Kenneth Dickstein; Marco Vicenzi et al. (2009). Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure A Comparative Analysis on Clinical and Prognostic Insights. (external link)
• Veselin Mitrovic; Petar Seferovic; Slobodan Dodic et al. (2009). Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure. (external link)
• Ivan Zeljkovic; Haran Burri; Alexander Breitenstein et al. (2018). Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. (external link)
• Stein Ørn; Unni M. Breland; Tom Eirik Mollnes et al. (2009). The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction. (external link)
• Masatake Kobayashi; Adriaan A. Voors; Wouter Ouwerkerk et al. (2021). Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. (external link)
• Trygve Sørdahl Hall; Stein Ørn; Faiez Zannad et al. (2022). The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. (external link)
• Stefano Coiro; Nicolas Girerd; Patrick Rossignol et al. (2017). Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. (external link)
• Jasper Tromp; Sahiddah Bamadhaj; John G. Cleland et al. (2020). Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. (external link)
• Fraser M. Curran; U. Bhalraam; Mohapradeep Mohan et al. (2021). Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. (external link)
• Søren Lund Kristensen; Pardeep S. Jhund; Ulrik M. Mogensen et al. (2017). Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. (external link)
• Wilfried Mullens; Angelo Auricchio; Pieter Martens et al. (2020). Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. (external link)
• Torstein Hole; Kenneth Dickstein; Thomas Erik Gundersen et al. (1997). Calcium channel blockers in heart failure. (external link)
• Kai C. Wollert; Gerd P. Meyer; Jochen Müller-Ehmsen et al. (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction: The BOOST-2 randomised placebo-controlled clinical trial. (external link)
• S Orn; Stein Ørn; Cord Arend Manhenke et al. (2009). Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. (external link)
• Jasper Tromp; Adriaan A. Voors; Abhinav Sharma et al. (2020). Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. (external link)
• Wouter Ouwerkerk; Adriaan A. Voors; Stephan D. Anker et al. (2017). Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study. (external link)
• Adrian F. Hernandez; Christopher M. O'Connor; Randall C. Starling et al. (2009). Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). (external link)
• Camilla C.S. van der Hoef; Eva M. Boorsma; Johanna E. Emmens et al. (2023). Biomarker signature and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome. (external link)
• Valentina Bracun; Bart van Essen; Adriaan A. Voors et al. (2022). Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. (external link)
• Henry Krum; Barry Massie; William T. Abraham et al. (2011). Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. (external link)
• Alf Inge Larsen; Christian Hall; Pål Aukrust et al. (2003). Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. (external link)
• Dimitrios Farmakis; Jasper Tromp; Smaragdi Marinaki et al. (2023). Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF. (external link)
• Ify R. Mordi; Wouter Ouwerkerk; Stefan D. Anker et al. (2020). Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. (external link)
• Søren Lund Kristensen; Davide Castagno; Li Shen et al. (2020). Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. (external link)
• Stefan Störk; Ausra Kavoliuniene; Dragos Vinereanu et al. (2016). What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. (external link)
• Kenneth Dickstein (2005). Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?. (external link)
• Mariëlle Kloosterman; Bernadet T. Santema; Carolina Roselli et al. (2020). Genetic risk and atrial fibrillation in patients with heart failure. (external link)
• Viviane M. Conraads; Christi Deaton; Ewa Piotrowicz et al. (2012). Adherence of heart failure patients to exercise: barriers and possible solutions A position statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology. (external link)
• Alan Bulava; Přemysl Hájek; Josef Kautzner et al. (2018). Cardiac resynchronization therapy in the Czech Republic - Data from the EHRA CRT Survey II multicenter registry. (external link)
• H. Jaatun; S. Sutradhar; Kenneth Dickstein (2004). Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. (external link)
• S. Pocock; L. Wilhelmsen; Kenneth Dickstein et al. (2004). The data monitoring experience in the MOXCON trial. (external link)
• Michael Busch; Eldar Søreide; Hans Morten Lossius et al. (2006). Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. (external link)
• Torbjørn Omland; Kenneth Dickstein; Unni Syversen (2003). Association between plasma chromogranin A and long-term mortality after myocardial infarction. (external link)
• Koen W. Streng; Hans L. Hillege; Jozine M. ter Maaten et al. (2022). Clinical implications of low estimated protein intake in patients with heart failure. (external link)
• Cord Arend Manhenke; Stein Ørn; Ian Squire et al. (2011). The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. (external link)
• K. Malmberg; L. Rydén; H Wedel et al. (2005). Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. (external link)
• Vincent Galand; Cecilia Linde; Nicolas Lellouche et al. (2019). The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France. (external link)
• Kenneth Dickstein; H.J. Voogd; M.P. Miric et al. (2004). Effect of single doses of SLV306, an inhibitor of both neutral enclopepticlase and enclothelin-converting enzyme, on pulmonary pressures in congestive heart failure. (external link)
• Xavier Rossello; João Pedro Ferreira; John JV McMurray et al. (2019). Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. (external link)
• Gerasimos Filippatos; Sadiya Sana Khan; Andrew P. Ambrosy et al. (2015). International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): Rationale for and design of a global registry. (external link)
• Nigussie Bogale; Klaus Witte; Silvia Giuliana Priori et al. (2011). The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. (external link)
• Kenneth Dickstein; Camilla Jaqueline Hansine Normand; Stefan D. Anker et al. (2014). European Cardiac Resynchronization Therapy Survey II: rationale and design. (external link)
• Trygve Sørdahl Hall; Thomas Gero von Lueder; Faiez Zannad et al. (2018). Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. (external link)
• Tor Melberg; Robert Anders Burman; Kenneth Dickstein (2010). The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. (external link)
• Wouter Ouwerkerk; Joao P. Belo Pereira; Troy Maasland et al. (2023). Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure. (external link)
• Christian Hall; Halfdan Ihlen; Vernon Bonarjee et al. (2003). N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. (external link)
• Damian Łasocha; Maciej Sterliński; Mateusz Tajstra et al. (2019). Do we differ in terms of indications and demographics in cardiac resynchronisation recipients in Poland? Insights from the European CRT Survey II registry. (external link)
• A Hognestad; K Dickstein; Eivind S.p. Myhre et al. (2004). Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. (external link)
• Camilla Jaqueline Hansine Normand; Cecilia Linde; Nigussie Bogale et al. (2019). Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. (external link)
• Thomas Gero von Lueder; Nicolas Girerd; Dan Atar et al. (2015). Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative.. (external link)
• Camilla Jacqueline Hansine Normand; Nigussie Bogale; Cecilia Linde et al. (2024). National health expenditure per capita is associated with CRT implantation practice: findings from the ESC CRT Survey II with 11 088 patients. (external link)
• Daniela Dobre; John Kjekshus; Patrick Rossignol et al. (2018). Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. (external link)
• Camilla Jacqueline Hansine Normand; Cecilia Linde; Carina Blomström-Lundqvist et al. (2020). Adherence to ESC cardiac resynchronization therapy guidelines: Findings from the ESC CRT Survey II. (external link)
• Cecilia M. Linde; Camilla Jaqueline Hansine Normand; Nigussie Bogale et al. (2018). Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. (external link)
• George V Moukarbel; Zi-Fan Yu; Kenneth Dickstein et al. (2014). The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. (external link)
• Johanna Elisabeth Emmens; Donald J.L. Jones; Thong H. Cao et al. (2018). Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. (external link)
• Alf Inge Larsen; Øyvind Skadberg; Torbjørn Aarsland et al. (2009). B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. (external link)
• Toru Kondo; Azmil H. Abdul-Rahim; Atefeh Talebi et al. (2022). Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. (external link)
• Wouter Ouwerkerk; Tiew-Hwa K. Teng; Jasper Tromp et al. (2020). Effects of combined renin–angiotensin–aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. (external link)
• Wan Ting Tay; Tiew-Hwa Katherine Teng; Wouter Ouwerkerk et al. (2025). Quality of care delivery in patients with acute heart failure: insights from the international REPORT-HF registry. (external link)
• Stein Ørn; Cord Arend Manhenke; Iain B. Squire et al. (2007). Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: Relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. (external link)
• Piotr Ponikowski; Gerasimos Filippatos; Josep Comin Colet et al. (2015). The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. (external link)
• Marco Metra; Robert J. Mentz; Adrian F. Hernandez et al. (2016). Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). (external link)
• Niraj Varma; Peter Søgaard; Jeroen J. Bax et al. (2018). Interaction of left ventricular size and sex on outcome of cardiac resynchronization therapy among patients with a narrow QRS duration in the EchoCRT trial. (external link)
• Jonathan G. Howlett; Justin A. Ezekowitz; Mohua Podder et al. (2013). Global variation in quality of care among patients hospitalized with acute heart failure in an international trial findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). (external link)
• Jasper Tromp; B. Daan Westenbrink; Wouter Ouwerkerk et al. (2018). Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. (external link)
• Eerde H. Weening; Ali A. Al-Mubarak; Martin M. Dokter et al. (2023). Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease. (external link)
• Ify R. Mordi; Bernadet T. Santema; Mariëlle Kloosterman et al. (2019). Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. (external link)
• Alexandre Mebazaa; M. Birhan Yilmaz; Phillip Levy et al. (2015). Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. (external link)
• Gianluigi Savarese; Alicia Uijl; Wouter Ouwerkerk et al. (2022). Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. (external link)
• Wouter Ouwerkerk; Aeilko H. Zwinderman; Leong L. Ng et al. (2018). Biomarker-guided versus guideline-based treatment of patients with heart failure: Results from BIOSTAT-CHF. (external link)
• Wilfried Mullens; Jeroen Dauw; Finn Gustafsson et al. (2024). Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). (external link)
• Toru Suzuki; Yoshiyuki Yazaki; Adriaan A. Voors et al. (2018). Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF). (external link)
• Johanna E. Emmens; Martin H. de Borst; Eva M. Boorsma et al. (2022). Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. (external link)
• Jasper Tromp; Wouter Ouwerkerk; John G. Cleland et al. (2021). Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. (external link)
• George Markousis-Mavrogenis; Jasper Tromp; Wouter Ouwerkerk et al. (2022). Multimarker profiling identifies protective and harmful immune processes in heart failure: Findings from BIOSTAT-CHF. (external link)
• Mika Lehto; Steven M. Snapinn; Kenneth Dickstein et al. (2005). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAL experience. (external link)
• Pooja Dewan; Pardeep S. Jhund; Li Shen et al. (2018). Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. (external link)
• Koen W. Streng; Adriaan A. Voors; Hans L. Hillege et al. (2018). Waist-to-hip ratio and mortality in heart failure. (external link)
• G. Papiashvili; G. Machitidze; C. Linde et al. (2019). EUROPEAN CARDIAC RESYNCHRONIZATION THERAPY SURVEY II: COMPARISON OF RESULTS IN GEORGIA WITH OTHER COUNTRIES. (external link)
• Stein Ørn; Toril Ueland; Cord A Manhenke et al. (2012). Increased interleukin-1 beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. (external link)
• Pankaj Gupta; Adriaan A. Voors; Prashanth Patel et al. (2021). Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). (external link)
• Camilla Jaqueline Hansine Normand; Cecilia Linde; Jagmeet Singh et al. (2018). Indications for cardiac resynchronization therapy: a comparison of the major international guidelines. (external link)
• Alf Inge Larsen; Sigurd Lindal; Kate Myreng et al. (2013). Cardiac resynchronization therapy improves minute ventilation/carbon dioxide production slope and skeletal muscle capillary density without reversal of skeletal muscle pathology or inflammation. (external link)
• Michael S Kiernan; Deborah Wentworth; Gary Francis et al. (2012). Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. (external link)
• Muhammad Shahzeb Khan; Søren L. Kristensen; Muthiah Vaduganathan et al. (2021). Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. (external link)
• Anne M.S. Belonje; B. Daan Westenbrink; Adriaan A. Voors et al. (2009). Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. (external link)
• Kenneth Dickstein; John Kjekshus (2001). Comparison of baseline data, Initial course, and mannagment: Losartan Versus captopril following acute myocardial infarction (The OPTIMAAL Trial). (external link)
• Markku Sakari Nieminen; Johann Altenberger; Tuvia Ben-Gal et al. (2014). Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. (external link)
• Trygve Sørdahl Hall; Thomas Gero von Lueder; Faïez Zannad et al. (2019). Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. (external link)
• Christian Torp-Pedersen; Lars Køber; Jan E. Carlsen et al. (2008). A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. (external link)
• A. S. Westheim; Kenneth Dickstein; Thomas Erik Gundersen et al. (1999). Kronisk hjertesvikt - forslag til handlingsprogram. (external link)
• G. Michael Felker; Vic Hasselblad; W.H. Wilson Tang et al. (2012). Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. (external link)
• Li Shen; Brian Claggett; Pardeep S. Jhund et al. (2021). Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. (external link)
• Jozine M. ter Maaten; Pieter Martens; Kevin Damman et al. (2020). Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. (external link)
• Johanna E. Emmens; Congzhuo Jia; Leong L. Ng et al. (2021). Impaired high-density lipoprotein function in patients with heart failure. (external link)
• Tiny Jaarsma; Leonie Verheijden Klompstra; Tuvia Ben Gal et al. (2015). Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: The rationale, design and methodology of the HF-Wii study; A multicentre randomized controlled trial. (external link)
• Tiny Jaarsma; Leonie Klompstra; Turia Ben-Gal et al. (2020). Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial. (external link)
• Bernadet T. Santema; Michelle M.Y. Chan; Jasper Tromp et al. (2019). The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. (external link)
• Prateeti Khazanie; Gretchen M. Heizer; Vic Hasselblad et al. (2015). Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. (external link)
• Kenneth Dickstein; Torbjørn Aarsland; Christian Hall (1997). Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. (external link)
• Randi Furseth Klinge; A. Polis; Kenneth Dickstein et al. (1997). Effects of angiotensin II receptor blockage on N- terminal proatrial natriuretic factor plasma levels in chronic heart failure. (external link)
• Kieran F. Docherty; Li Shen; Davide Castagno et al. (2019). Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. (external link)
• Ridha I.S. Alnuwaysir; Niels Grote Beverborg; Martijn F. Hoes et al. (2021). Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. (external link)
• Knut Gjesdal; Kenneth Dickstein (1997). Digitalis - et gammelt, men stadig aktuelt medikament. (external link)
• S Orn; Stein Ørn; Cord Arend Manhenke et al. (2007). Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. (external link)
• Vernon V.S Bonarjee; Annika Rosengren; Steven M. Snapinn et al. (2006). Sex-based short- and long-term survival in patients following complicated myocardial infarction. (external link)
• João Pedro Ferreira; Kevin Duarte; Marc A Pfeffer et al. (2018). Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. (external link)
• Haye H. van der Wal; Niels Grote Beverborg; Kenneth Dickstein et al. (2019). Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. (external link)
• JJ McMurray; Stamatis Adamopoulos; S D Anker et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. (external link)
• Jean-Claude Daubert; Leslie Saxon; Philip B Adamson et al. (2012). 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (external link)
• Jean-Claude Daubert; Leslie Saxon; Philip B Adamson et al. (2012). 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. (external link)
• Johanna Elisabeth Emmens; Jozine M. ter Maaten; Kevin Damman et al. (2019). Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. (external link)
• Nigussie Bogale; Silvia Giuliana Priori; John G.F. Cleland et al. (2012). The European CRT Survey: 1 year (9-15 months) follow-up results. (external link)
• Masatake Kobayashi; Susan Stienen; Jozine M. ter Maaten et al. (2020). Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. (external link)
• Joanne Simpson; Pardeep S. Jhund; Lars H. Lund et al. (2020). Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. (external link)
• Jens Cosedis Nielsen; Josef Kautzner; Ruben Casado-Arroyo et al. (2020). Remote monitoring of cardiac implanted electronic devices: Legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. (external link)
• George Markousis-Mavrogenis; Waldemar B. Minich; Ali A. Al-Mubarak et al. (2023). Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. (external link)
• I Jsbrand T Klip; Adriaan A. Voors; Stefan D Anker et al. (2011). Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. (external link)
• Philippe Gabriel Steg; Stefan James; Dan Atar et al. (2012). ESC Guidelines for the management of acute myocardial infarction in patientspresenting with ST-segment elevation. (external link)
• Thong H. Cao; Donald J.L. Jones; Adriaan A. Voors et al. (2019). Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. (external link)

Academic literature review

• Marco Metra; Piotr Ponikowski; Kenneth Dickstein et al. (2007). Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. (external link)
• Kenneth Dickstein (2005). Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. (external link)
• Ewa Piotrowicz; Massimo F. Piepoli; Tiny Jaarsma et al. (2016). Telerehabilitation in heart failure patients: The evidence and the pitfalls. (external link)
• Juhani Knuuti; William Wijns; Antti Saraste et al. (2020). 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. (external link)
• Kenneth Dickstein; Judith Bebchuk; Janet Wittes (2012). The High-Risk Myocardial Infarction Database Initiative. (external link)
• Markku S. Nieminen; Kenneth Dickstein; Cândida Fonseca et al. (2015). The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. (external link)
• Mihai Gheorghiade; Ferenz Follath; Piotr Ponikowski et al. (2010). Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. (external link)
• Faiez Zannad; Angeles Alonso Garcia; Stefan D. Anker et al. (2013). Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. (external link)
• Kenneth Dickstein (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). (external link)
• Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos et al. (2008). Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. (external link)
• Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos et al. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. (external link)
• Camilla Jaqueline Hansine Normand; David M. Kaye; Thomas J. Povsic et al. (2019). Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. (external link)
• Leonardo De Luca; Alexandre Mebazaa; Gerasimos Filippatos et al. (2008). Overview of emerging pharmacologic agents for acute heart failure syndromes. (external link)
• K Dickstein; A Cohen-Solal; G Filippatos et al. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). (external link)
• Karl Swedberg; John Cleland; Martin R. Cowie et al. (2008). Successful treatment of heart failure with devices requires collaboration. (external link)

Conference lecture

• Ingvild Margreta Morken; Ove Nordstokke; Leonora Hofker Berg et al. (2005). Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre. (external link)
• S Orn; C Manhenke; Thor Ueland et al. (2008). C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction. (external link)
• A. Larsen; S. Lindal; Pål Aukrust et al. (2001). Effect of exercise training on muscle fibre characteristics in patients with heart failure. (external link)
• Kenneth Dickstein (2002). Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial. (external link)
• Kenneth Dickstein (2002). Outpatient heart failure management programs – 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure. (external link)
• Kenneth Dickstein (2002). Clinical implications of losartan in the OPTIMAAL study. (external link)
• Kenneth Dickstein (2002). Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions. (external link)
• Christian Hall; T. A. Langvik; Torbjørn Aarsland et al. (1996). N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis. (external link)
• Kenneth Dickstein (2002). Results of recent trials in patients with heart failure following myocardial infarction. (external link)
• Kenneth Dickstein (2002). Angiotensin II antagonists; are they established therapy in heart failure?. (external link)
• Kenneth Dickstein (2002). The role of angiotensin II antagonists in heart failure and following myocardial infarction. (external link)
• Kenneth Dickstein (2002). Beta-blockers should be withdrawn in decompensated heart failure patients. (external link)
• Kenneth Dickstein (2002). State of the art management of myocardial infarction. (external link)
• Kenneth Dickstein (2002). ARBs are as good as ACE inhibitors. (external link)
• Kenneth Dickstein (2002). Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial. (external link)

Editorial/Leader article

• Kenneth Dickstein (2010). Inpatients are sicker than outpatients; finally it's evidence-based. (external link)
• Kenneth Dickstein (2015). Increased pulmonary vascular resistance, right ventricular dysfunction, and reversible pulmonary vasoconstriction in type 2 pulmonary hypertension: Who has it and are we missing a potential therapeutic target in patients with heart failure?. (external link)
• Kenneth Dickstein (2015). Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? the power of a large, high-quality registry to illuminate major clinical issues. (external link)
• Camilla Jaqueline Hansine Normand; Kenneth Dickstein (2018). Guideline recommendations for cardiac resynchronization therapy evolve but does clinical practice match the pace?. (external link)
• John J.V. McMurray; William T. Abraham; Kenneth Dickstein et al. (2012). Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. (external link)
• Kenneth Dickstein (2017). Early clinical benefit after cardiac resynchronization therapy: fortunately, QRS width and ejection fraction are still the best predictors. (external link)
• Torkel Steen; Kenneth Dickstein (2017). Do real world data support and extend our ability to predict reverse remodelling following cardiac resynchronization therapy based on QRS morphology and width?. (external link)
• Kenneth Dickstein (2012). Beware the dangers of the reply-all button. (external link)
• Kenneth Dickstein (2011). Cardiac myosin activation: will theory and practice coincide?. (external link)
• Kenneth Dickstein (2000). Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. (external link)
• Kenneth Dickstein (2001). What should be the focus in the management of patients with heart failure? The importance of peripheral vision. (external link)
• V. Bonarjee; Kenneth Dickstein (2001). Management of patients with heart failure; are internists as good as cardiologists?. (external link)
• Kenneth Dickstein (2001). ACE inhibitors in heart failure: are they irreplaceable?. (external link)
• Kenneth Dickstein (2002). In the treatment of heart failure, faster may not always be better. (external link)
• Camilla Jaqueline Hansine Normand; Kenneth Dickstein (2016). Does the presence of mitral regurgitation strengthen or weaken the indication for cardiac resynchronization therapy?. (external link)
• Kenneth Dickstein (2005). C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure. (external link)
• M Nicholls; Kenneth Dickstein (2009). Spotlight: Kenneth Dickstein, MD, PhD, FESC. (external link)
• Kenneth Dickstein (2009). Diagnosing Acute Heart Failure. The Mathematician and the Clinician. (external link)
• Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos et al. (2008). ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. (external link)
• Anna Strömberg; Kenneth Dickstein (2008). What is new and of special interest to nurses in the 2008 ESC guidelines for diagnosis and treatment of acute and chronic heart failure?. (external link)
• Kenneth Dickstein (2013). Cardiac resynchronization therapy in seniors: when are we too old to deserve a device that makes us feel better and improves clinical outcomes?. (external link)
• Kenneth Dickstein (2010). Response to Coceani: Cardiac Resynchronization Therapy Has Earned Its Class I Recommendation and Continues to Thrive Under Scrutiny. (external link)
• Helen Jaques; Kenneth Dickstein (2010). Personal experiences of emigre cardiologist: Kenneth Dickstein MD, PhD, FESC A tale of enchantment. (external link)
• Henry Krum; Barrie Massie; William T. Abraham et al. (2013). Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. (external link)
• Kenneth Dickstein (2011). Chronic right ventricular pacing, adverse remodelling, and CRT: an ounce of prevention?. (external link)
• Camilla Jaqueline Hansine Normand; Kenneth Dickstein (2015). Predicting outcomes following CRT: The quest continues. (external link)

Professional article

• Torbjørn Holm; Svein Færestrand; Alf Inge Larsen et al. (2014). Kardial resynkroniseringsterapi ved hjertesvikt – norske retningslinjer.. (external link)

Letter to the editor

• Jasper Tromp; Sahiddah Bamadhaj; John G F Cleland et al. (2020). Correction to: Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. (external link)
• Muhammad Zubair Israr; Andrea Salzano; Yoshiyuki Yazaki et al. (2020). Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF. (external link)
• Kenneth Dickstein (2004). Appearances can deceive: even brave hearts can fail. (external link)
• Emil Wolsk; Brian Claggett; Rafael Diaz et al. (2017). Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes mellitus. (external link)
• Alf Inge Larsen; Kenneth Dickstein (2004). Can sedentary patients with heart failure achieve the beneficial effect of exercise training without moving?. (external link)
• Alf Inge Larsen; Kenneth Dickstein (2004). BNP in acute coronary syndromes: the heart expresses its suffering. (external link)
• Hertzel C. Gerstein; Emil Wolsk; Brian Claggett et al. (2022). Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial. (external link)
• Kenneth Dickstein (2001). The plight of the peer reviewer (letter). (external link)
• Kenneth Dickstein (2006). Clinical trials update from the European Society of Cardiology Meeting 2005: CIBIS-III. response to correspondence from R. Willenheimer et al. (external link)
• Kenneth Dickstein (2001). Er det farlig å bli innlagt i helgen?. (external link)
• John J.V. McMurray; Kenneth Dickstein; Lars V. Køber (2016). Pioglitazone after ischemic stroke or transient ischemic attack: The authors reply. (external link)
• Marco Metra; Dirk Brutsaert; Kenneth Dickstein et al. (2007). Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. (external link)
• Alf Inge Larsen; Øyvind Skadberg; Torbjørn Aarsland et al. (2008). B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. (external link)
• Kenneth Dickstein (2009). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides: reply. (external link)
• L Kennedy; Kenneth Dickstein; S. Anker et al. (2005). The prognostic importance of body mass index after complicated myocardial infarction. (external link)
• Kenneth Dickstein; Tiny Jaarsma (2005). Heart failure management programmes: delivering the message. (external link)
• J. McMurray; K Swedberg; M. Pfeffer et al. (2005). Angiotensin receptor blockers and myocardial infarction: Analysis of evidence is incomplete and inaccurate. (external link)
• V. Tuseth; HJ Jaatun; Kenneth Dickstein (2005). Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. (external link)
• Kenneth Dickstein; Erland Erdmann (2005). Establishing best practice in the management of chronic heart failure - Introduction. (external link)
• Trond Johan Cooper; Pierpaolo Pellicori; Anastasia Ushakova et al. (2022). Reply to ‘Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease’. (external link)
• Jasper Tromp; Wouter Ouwerkerk; John G.F. Cleland et al. (2022). A global perspective of racial differences and outcomes in patients presenting with acute heart failure. (external link)
• Kenneth Dickstein; John J.V. McMurray (2009). Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma? Reply. (external link)
• Kenneth Dickstein; John Kjekshus (2002). The OPTIMMAL trial: losartan or captopril after acute myocardial infarction. (external link)
• Kenneth Dickstein (2002). Angiotensin receptor blockers-finally the evidence is coming in: IDNT and RENAAL. (external link)
• Stein Ørn; Kenneth Dickstein (2007). Reduce the risk of reinfarction and related complications after myocardial infarction - The reply. (external link)

Doctoral thesis (PhD)

• Kenneth Dickstein (1991). Cardiopulmonary exercise testing after myocardial infarction: Evaluation of the methodology and its use in assessing the effect of pharmacologic intervention on functional capacity. (dr.med.). (external link)
• Alf Inge Larsen; Kenneth Dickstein (2004). Exercise training in congestive heart failure: evaluation of test protocols and effect on neurohormones, cytokines, heart rate variability and skeletal muscle histology. (external link)

Conference poster

• Stein Ørn; C Manhenke; Vernon Bonarjee et al. (2007). Temporal changes between infarct size and ejection fraction following primary PCI assessed by cardiac magnetic resonance. (external link)
• Kenneth Dickstein; Steven M. Snapinn (2002). Prediction of mortality and morbidity following myocardial infarction. (external link)
• Stein Ørn; John Cleland; John Kjekshus et al. (2002). Myocardial infarction is the most common underlying cause of death in patients with heart failure following myocardial infarction. (external link)
• Markku Nieminen; Andreas Zeiher; Eivind Myhre et al. (2002). The effect of revascularisation rate on prognosis of high-risk acute myocardial infarction patients. An OPTIMAAL substudy. (external link)
• Hans Jaatun; Steven M. Snapinn; Kenneth Dickstein (2002). Smoking and cardiovascular risk following myocardial infarction. (external link)
• T Omland; A Aakvaag; VVS Bonarjee et al. (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. (external link)
• Trygve Sørdahl Hall; S Orn; F. Zanned et al. (2020). The association of smoking to cardiovascular death differs according to age and sex following myocardial infarction complicated by heart failure or left ventricular dysfunction. (external link)
• Øyvind Hetland; Kenneth Dickstein; Dennis W.t. Nilsen (2001). Activation of coagulation in patients with acute chest pain syndromes as determined by fibrin monomer (soluble fibrin). (external link)
• Ø. Hegland; Kenneth Dickstein; Jan P. Larsen (2001). Effect of simvastatin in preventing progression of carotid artery stenosis. (external link)
• T Omland; A Aakvaag; VVS Bonarjee et al. (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. (external link)

Conference abstract

• Stein Ørn; Tor Harald Melberg; M Jorgensen et al. (2013). Early discharge (< 3 days) following primary PCI is safe in low risk patients. (external link)
• Kenneth Dickstein (2013). ESC Heart Failure Guidelines 2012-a review. (external link)
• Cord Arend Manhenke; S Orn; T Leland et al. (2009). Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. (external link)
• Aina Hognestad; Kenneth Dickstein; Ragnhild. Wergeland et al. (2003). Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. (external link)
• N Bogale; S Orn; Steven M. Snapinn et al. (2004). Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. (external link)
• Aina Hognestad; Kenneth Dickstein; Ragnhild Wergeland et al. (2003). Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. (external link)
• Michael S Kiernan; James D Neaton; Felipe Martinez et al. (2010). Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. (external link)
• Adrian F. Hernandez; Christopher M. O'Connor; Randall C. Starling et al. (2010). Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). (external link)
• Cord Arend Manhenke; Stein Ørn; Iain B. Squire et al. (2007). The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. (external link)
• D. Dobre; F. Zannad; John Kjekshus et al. (2013). The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. (external link)
• Trygve Brügger-Andersen; Volker Pønitz; Steven M. Snapinn et al. (2004). Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. (external link)
• M. Lehto; Steven M. Snapinn; Kenneth Dickstein et al. (2004). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. (external link)
• S.D. Anker; A.L. Clark; M.K. James et al. (2004). Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. (external link)
• C. Manhenke; S. Ørn; A. Radauceanu et al. (2004). The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. (external link)
• J. Kjekshus; Steven M. Snapinn; A. Hognestad et al. (2004). Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. (external link)
• S. Ørn; I.B. Squire; C. Manhenke et al. (2004). Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. (external link)
• S. Ørn; C. Manhenke; E. Nagel et al. (2004). The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. (external link)
• SD Anker; AL Clark; MK James et al. (2004). Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. (external link)
• Kenneth Dickstein (2004). What's new in the management of heart failure?. (external link)
• J Comin-Colet; M Lainscak; Kenneth Dickstein et al. (2010). Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. (external link)
• J Gravning; Stein Ørn; T Edvardsen et al. (2010). Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. (external link)
• Stein Ørn; ZF Yu; R Hou et al. (2010). Smokers spend shorter time in hospital than non-smokers following complicated AMI. (external link)
• Stein Ørn; Cord A Manhenke; IB Squire et al. (2010). Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. (external link)
• SC Inglis; MA Pfeffer; F Zannad et al. (2010). Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). (external link)
• I Gustafsson; L Mellbin; Kenneth Dickstein et al. (2010). NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. (external link)

Academic book chapter

• Stuart Pocock; Lars Wilhelmsen; Kenneth Dickstein et al. (2006). Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial. (external link)
• Curt Manhenke; Kenneth Dickstein (2002). Heart failure and Coronary Artery Disease. (external link)
• Camilla Jacqueline Hansine Normand; Kenneth Dickstein (2019). CRT Devices in Heart Failure: Does the Patient Need a Pacemaker or Defibrillator?. (external link)

Popular science article

• Kenneth Dickstein; Steven M. Snapinn (2003). How should we analyse hospitalisation data in clinical trials?. (external link)
• Kenneth Dickstein (2003). What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?. (external link)

Working paper

• Kenneth Dickstein (2004). How and when to use angiotensin-receptor-blockers in heart failure: some theory evidence and practical guidelines. (external link)

Journal corrigendum

• Bernadet T. Santema; Michelle M. Y. Chan; Jasper Tromp et al. (2021). Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure (Clinical Research in Cardiology, (2020), 109, 3, (331-338), 10.1007/s00392-019-01513-y). (external link)
• Deepti Ranganathan; Zain Sharif; Theodore Murphy et al. (2020). Correction to: CRT Survey II: a European Society of Cardiology (ESC) survey of cardiac resynchronization therapy—an Irish subset analysis (Irish Journal of Medical Science (1971 -), (2020), 189, 3, (895-905), 10.1007/s11845-020-02173-y). (external link)

See a complete overview of publications in NVA.